Chlorpromazine

CHEMBL71 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

318.9 g/mol

LogP

5.2

Phase

4

The first antipsychotic medication, introduced in the 1950s, that blocks dopamine D2 receptors and multiple other neurotransmitter receptors, used for the treatment of schizophrenia, mania, nausea, and intractable hiccups. Its discovery revolutionized psychiatry and led to the deinstitutionalization of many psychiatric patients. It carries significant risks of extrapyramidal symptoms, tardive dyskinesia, metabolic effects, and sedation.

Molekularmasse

318,9000 g/mol

LogP

5,20

TPSA

31,80 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Glaucoma Schizophrenia Bipolar Disorder Gastroesophageal Reflux Disease Stroke

Wirkmechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21

InChI

InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

Molecular Formula

C17H19ClN2S

HBD / HBA

- / 3

Rotierbare Bindungen

4

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The first antipsychotic medication, introduced in the 1950s, that blocks dopamine D2 receptors and multiple other neurotransmitter receptors, used for the treatment of schizophrenia, mania, nausea, and intractable hiccups. Its discovery revolutionized psychiatry and led to the deinstitutionalization of many psychiatric patients. It carries significant risks of extrapyramidal symptoms, tardive dyskinesia, metabolic effects, and sedation.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Chlorpromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL71. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2726. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Chlorpromazine auf PillFYI

Struktur

Schnelldaten

Formel: C17H19ClN2S
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.